Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Mark Udy

Physician Assistant, Medical St George, UT Physician Assistant

NPI 1659405314 CMS profile 10921334

617 E Riverside Dr Ste 301, St George, UT 84790

Open in the dashboard

General payments

$9,254

341 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Udy of St George, UT is reported in the CMS Open Payments database as having received $9,254 across 341 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,394 51
2024 General $1,445 60
2023 General $1,456 62
2022 General $1,143 66
2021 General $3,815 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Udy
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Mark Udy were reported at $1,394. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Mark Udy Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $3,815 $156 $41–$563 $132
2022 $1,143 $185 $55–$649 $149
2023 $1,456 $199 $58–$717 $160
2024 $1,445 $206 $62–$740 $164
2025 $1,394 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Boston Scientific Corporation $5,082 122 payments
  2. AbbVie, Inc. $1,102 46 payments
  3. Pfizer Inc. $306 16 payments
  4. Nevro Corp. $254 10 payments
  5. Lundbeck LLC $244 14 payments
  6. Relievant Medsystems, Inc. $239 7 payments
  7. Medtronic, Inc. $211 14 payments
  8. Teva Pharmaceuticals USA, Inc. $184 9 payments
  9. Salix Pharmaceuticals, a division of Bausch Health US, LLC $172 10 payments
  10. Abbott Laboratories $170 22 payments
  11. Other $1,290 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $7,253 330 payments
  2. Travel and Lodging $2,001 11 payments
Products named General payments · program years 2021–2025
  1. WAVEWRITER ALPHA Pain Management $1,460 7 payments
  2. WAVEWRITER ALPHA WaveWriter Alpha $1,084 6 payments
  3. GENERAL PAIN MANAGEMENT $474 27 payments
  4. UBRELVY $436 22 payments
  5. General - Pain Management $406 24 payments
  6. CoverEdge 32 $388 11 payments
  7. QULIPTA $386 22 payments
  8. BOTOX $336 10 payments
  9. NURTEC ODT $306 16 payments
  10. Artisan $257 7 payments
  11. Other $4,015 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

3,983

Median for Physician Assistant: 241

Drug cost

$425,855

Median for Physician Assistant: $4,110

Branded share of claims

42.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 29 $48,431
Nucynta Er Tapentadol Hcl Brand 28 $46,145
Xtampza Er Oxycodone Myristate Brand 43 $30,663
Nucynta Tapentadol Hcl Brand 22 $30,398
Fentanyl Generic 201 $25,579
Botox Onabotulinumtoxina Brand 20 $25,469
Oxycontin Oxycodone Hcl Brand 30 $24,691
Qulipta Atogepant Brand 23 $23,880
Movantik Naloxegol Oxalate Brand 47 $19,617
Ubrelvy Ubrogepant Brand 12 $19,298

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 19 billing codes

Paid by Medicare

$190,392

Of which drugs: $43,076

Medicare patients

365

Average age 74

Services billed

12,094

204 women, 161 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Depression 42%
Diabetes 28%
Chronic kidney disease 28%
Ischemic heart disease 27%
Osteoporosis 22%
Heart failure 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, onabotulinumtoxina, 1 unit J0585 Office 15 8,100 $39,373
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 107 1,098 $783

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
BOTOX
  • AbbVie, Inc. $229
$229 20 8,100
UBRELVY
  • AbbVie, Inc. $102
$102 12 —
NURTEC ODT
  • PFIZER INC. $100
$100 29 —
QULIPTA
  • AbbVie, Inc. $85
$85 23 —
RELISTOR
  • Salix Pharmaceuticals, a division of Bausch Health US, LLC $53
$53 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

341 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Utah

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record